And then there were … oh, forget it: We’ve given up trying to count the number of CRISPR companies, but we can tell you that one more came out of stealth mode on Thursday. After a year spent wooing investors, hiring, and refining its plans, Mammoth Biosciences, co-founded by CRISPR developer Jennifer Doudna, is announcing its entry into the ever-more-crowded fields of diagnostics and genome-editing, and hoping to find a sweet spot at their intersection.

“Mammoth Biosciences is all about building a CRISPR-based platform for disease detection,” said CEO Trevor Martin, who got a Ph.D. in genetics and statistics from Stanford in 2016.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy